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Gene-diet interaction studies have reported that individual variations in phenotypic traits may be due to variations in individual
diet. Our study aimed to evaluate (i) the association of ADRB2 rs1042713 with obesity and obesity-related metabolic parameters
and (ii) the effect of dietary nutrients on these associations in Malaysian adults. ADRB2 genotyping, dietary, physical activity,
anthropometric, and biochemical data were collected from 79 obese and 99 nonobese individuals. Logistic regression revealed no
association between ADRB2 rs1042713 and obesity (p � 0.725). However, the carriers of G allele (AG+GG genotypes) of
rs1042713 were associated with increased odds of insulin resistance, 2.83 (CI� 1.04–7.70, adjusted p � 0.042), in the dominant
model, even after adjusting for potential confounders. Obese individuals carrying the G allele were associated with higher total
cholesterol (p � 0.011), LDL cholesterol levels (p � 0.008), and total cholesterol/HDL cholesterol ratio (p � 0.048), compared to
the noncarriers (AA), even after adjusting for potential confounders. Irrespective of obesity, the carriers of GG genotype had
significantly lower fasting glucose levels with low saturated fatty acid intake (<7.3% of TE/day) (4.92± 0.1mmol/L vs
5.80± 0.3mmol/L, p � 0.011) and high intake of polyunsaturated fatty acid:saturated fatty acid ratio (≥0.8/day) (4.83± 0.1mmol/
L vs 5.93± 0.4mmol/L, p � 0.006). Moreover, the carriers of GG genotype with high polyunsaturated fatty acid intake (≥6% of TE/
day) had significantly lower HOMA-IR (1.5± 0.3 vs 3.0± 0.7, p � 0.026) and fasting insulin levels (6.8± 1.6 µU/mL vs
11.4± 2.1 µU/mL, p � 0.036). *ese effects were not found in the noncarriers (AA). In conclusion, G allele carriers of ADRB2
rs1042713 were associated with increased odds of insulin resistance. Obese individuals carrying G allele were compromised with
higher blood lipid levels. Although it is premature to report gene-diet interaction on the regulation of glucose and insulin levels in
Malaysians, we suggest that higher quantity of PUFA-rich food sources in regular diet may benefit overweight and obese
Malaysian adults metabolically. Large-scale studies are required to replicate and confirm the current findings in the
Malaysian population.
1. Background
Obesity and related chronic diseases have become the
leading causes of morbidity and mortality worldwide. Long-
term consumption of energy dense food coupled with
sedentary lifestyle are the main contributors to the devel-
opment of obesity and related complications [1]. Multiple
genetic loci determined by genome-wide association studies
(GWAS) have been found to be associated with increased
susceptibility to obesity, diabetes, and dyslipidemia [2].
Earlier studies have reported on the adrenergic receptor
system for its role in the stimulation of thermogenesis and in
activating lipid mobilization from the fat stores. With re-
spect to this, the beta-2 adrenoceptor gene is a candidate
gene since it is the dominating lipolytic receptor in the
human white adipose tissue [3]. It stimulates lipid
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mobilization through lipolysis in adipocytes and regulates
body fat accumulation and energy expenditure [4].
A strong association between obesity and a single nu-
cleotide polymorphism located at codon 16 substituting
arginine for glycine (rs1042713/Arg16Gly) has been re-
ported by Large et al. [5]. Masuo et al. reported that insulin-
resistant subjects had higher frequencies of the G allele of
rs1042713 [6]. Total body fat mass and blood pressure levels
were higher in nonobese and nonhypertensive men with G
allele in the Japanese population.*e authors speculated that
insulin resistance could, in part, be determined by the ge-
netic variant of the beta-2 adrenoceptor gene and that
polymorphism and higher plasma adrenaline could increase
insulin resistance, adiposity, and high blood pressure in their
subjects. *us, the G allele could lead to heightened sym-
pathetic nerve activity, insulin resistance, and higher blood
pressure and adiposity in nonobese and nonhypertensive
individuals. Other studies have adequately reported that
insulin resistance was strongly associated with heightened
sympathetic nerve activity [7]. In other words, adrenergic
receptor defects lead to the sympathetic nervous system over
activity that may play a role in the development of insulin
resistance, hypertension, and obesity [8].
A study on the Swedish population reported that ADRB2
rs1042713 was significantly associated with elevated central
body fat, systolic blood pressure, serum leptin, and tri-
glyceride levels but not with obesity [9]. Studies from Saudi
Arabia reported significant association between ADRB2
rs1042713 polymorphism and the development of insulin
resistance, dyslipidemia, overweight, and obesity [10, 11].
However, findings from Asian populations (Japanese and
Korean) reported negative association between obesity and
ADRB2 gene polymorphisms. Moreover, these studies did
not investigate interaction of gene variants with dietary
nutrients [12, 13].
Individual or population differences in the development
of obesity-related metabolic diseases may result not only
from genetic variation but may also be the modulatory effect
of dietary nutrients on gene and gene variants [14]. In the
Malaysian population, relatively little is known with respect
to the interaction between dietary nutrients and ADRB2
gene variations on obesity, insulin resistance, and glucose
homeostasis. It is believed that early identification of the
candidate gene variants and their interaction with diet may
allow for the provision of good quality personalised dietary
recommendation to achieve effective weight loss and re-
duction in metabolic risk factors [15]. Although a couple of
intervention studies have reported lipid outcomes associated
with ADRB2 rs1042713, there is no such study done in
Malaysian adults. Since there has been conflicting results
with respect toADRB2 rs1042713 between Asian, Caucasian,
and Arabic populations, the current study on the Malaysian
population is valuable and will shed light and add to the
existing evidence on gene variants and phenotypic outcomes
and influence of diet on the latter. To the best of our
knowledge, this is the first study in Malaysian adults that
investigates the interaction between ADRB2 rs1042713 and
dietary nutrients on obesity-related metabolic traits. *is
study is nested in a broader study investigating the
association of single nucleotide polymorphisms in genes that
have widely been reported to influence obesity and obesity-
related metabolic disorders in human individuals. In an
earlier publication, we have reported that FTO rs9930506
may interact with dietary protein and Vitamin E intake and
modulate hsCRP levels in our Malaysian participants [16].
*e aim of the current study was to evaluate (i) the effect of
ADRB2 rs1042713 on obesity and obesity-related anthro-
pometric and blood biochemical parameters and (ii) the
influence of diet on the association between ADRB2
rs1042713 and obesity phenotypes, in Malaysian adults.
2. Methods
2.1. EthicalApproval. *is study was reviewed and approved
by the University of NottinghamMalaysia Campus (UNMC)
Science and Engineering Research Ethics Committee and
was registered under Medical Research and Ethics Com-
mittee (MREC) of National Medical Research Registry
(Research ID: 25110), Ministry of Health Malaysia (MOH).
Written informed consent was obtained from all
participants.
2.2. Study Design. *is cross-sectional study was conducted
from 2014–2017 on Malaysian adults aged between 18 and
74 years. *e study investigated (i) the association between
ADRB2 rs1042713 with obesity and insulin resistance; (ii)
the association between ADRB2 rs1042713 and phenotypes
in obese and nonobese individuals; and (iii) the interaction
between ADRB2 rs1042713 and dietary nutrients on phe-
notypic traits.
2.3. Participant Selection. Detailed information on the study
design and methods can be found in our earlier publication
[16]. *erefore, with respect to assessment of anthropo-
metric parameters, dietary nutrients analysis, and physical
activity level assessment, we refer the readers to our earlier
publication [16].
2.4. Blood Collection and Biochemical Analysis. 10–12 hour
fasting blood was collected into vacutainer tubes containing
fluoride oxalate for plasma glucose analysis and vacutainer
tubes with clot activator and gel (Becton Dickinson, Oxford,
United Kingdom) for serum lipid profile (total cholesterol,
triglyceride, and HDL cholesterol levels), insulin, and high-
sensitivity C-reactive protein (hsCRP) analysis. *e analysis
for above biochemical parameters were assessed using
Abbott Architect CI8200 Automatic System following the
manufacturer’s instructions. Homeostatic model assessment to
estimate insulin resistance (HOMA-IR) was calculated by
multiplying fasting plasma glucose (mmol/L) by fasting serum
insulin (µU/ml) and divided by 22.5 [17]. Low-density lipo-
protein (LDL) cholesterol was calculated using the Friedewald
formula: LDL cholesterol� total cholesterol− ((triglyceride/
5) +HDL cholesterol) [18].*is information has been reported
in our earlier publication [16]. *is study investigates ADRB2
rs1042713 gene polymorphism in the same population with the
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aim to evaluate (i) the effect of ADRB2 rs1042713 on obesity
and obesity-related anthropometric and blood biochemical
parameters and (ii) the influence of diet on the association
between ADRB2 rs1042713 and obesity phenotypes.
2.5. Genotyping of ADRB2 rs1042713 Gene Polymorphism.
Five milliliters of whole blood was drawn from an ante-
cubital vein into vacutainer tubes (Becton, Dickinson and
Co., Franklin Lakes, NJ) containing EDTA. *e genomic
DNA was extracted from leukocytes using the MasterPure
DNA Purification kit (Lucigen Corporation Middleton, WI,
USA) according to the manufacturer’s instructions. DNA
samples were stored at −20°C until use. A DNA fragment of
310 bp containing rs1042713 was amplified by using poly-
merase chain reaction (PCR) for the identification ofADRB2
rs1042713 gene polymorphism with specific primers (for-
ward primer: 5′-CCGCCGTGGGTCCGCC-3′ and reverse
primer: 5′-CCATGACCAGATCAGCAC-3′) derived from
an earlier study [19]. PCR was performed using 5 µl of
genomic DNA (∼1 ng/µl), 0.2 µM forward primer, and re-
verse primer with 5 µl of Taq 5X Master Mix. *ermal cy-
cling was performed as follows: initial denaturing at 95°C for
5min; 35 cycles of denaturation at 94°C for 45 s, annealing at
64°C for 40 s and extension at 72°C for 45 sec, and then a final
extension at 72°C for 5min. *e amplicons were verified by
using electrophoresis on 2% agarose gel and visualized under
ultraviolet illumination after staining by ethidium bromide.
*e verified amplicons were then sequenced by using
BigDye® terminator v3.1 cycle sequencing kit chemistry.
2.6. Power and Sample Size Calculation. We performed
power calculation using software QUANTO, Version 1.2.4,
to find theminimum detectable effect for a given sample size.
*is calculation takes into account the type 1 error rate of
0.05, and the population prevalence of insulin resistance
(using a cut off of HOMA-IR≥ 1.7) of 45%, as reported in the
present study. Given that the minor allele frequency (A) of
ADRB2 rs1042713 in our study was 0.49 with 57 insulin-
resistant and 69 non-insulin-resistant participants, we had
68.2% power to detect an effect of 2.83 (odds ratio)
(dominant model).
With regard to the gene-diet interaction, given that the
mean of fasting glucose levels in our population was
5.2mmol/L, with a SD of 2.0, environmental effect (differ-
ences of fasting glucose levels between high and low PUFA :
SFA ratio) of −0.4 (5.0mmol/L–5.4mmol/L), genetic effect
(differences of fasting glucose levels between the carriers of
G allele of ADRB2 rs1042713 and the noncarriers (A)) of 0.3
(5.4mmol/L− 5.1mmol/L), and interaction effect of −1.1
(4.83mmol/L–5.93mmol/L), a power of 61% for the gene-
diet interaction was computed.
2.7. Statistical Analysis. Statistical analysis was performed
using the statistical package for social sciences (IBM SPSS
statistic, Chicago, IL, USA, version 22). Data were expressed
as mean± standard error (SE) or number (percentage). Log
transformation was performed to transform nonnormally
distributed data into normally distributed data. Independent
t-test and chi-squared test were performed to assess the
differences between the two genotype groups (AA vs
AG+GG) on baseline continuous variables and categorical
variables, respectively. Allele frequency was estimated by
gene counting and chi-squared test was used to assess de-
viation from Hardy–Weinberg equilibrium (HWE) [20]. To
study the effect of ADRB2 rs1042713 on obesity, data were
dichotomised into obese and nonobese groups (obesity was
defined by BMI≥ 27.5 kg/m2) [21]. *e AA genotype of
ADRB2 rs1042713 was used as the reference group in both
codominant and dominant models, whereas the combina-
tion of AG and GG genotypes was used as the reference
group in recessive model. Odds ratios (ORs) with 95%
confidence intervals (95% CIs) were estimated for each
genotype by logistic regression to determine the odds of
obesity associated with gene variants, after adjusting for
covariates age, gender, physical activity status, smoking
status, and alcohol consumption. Same analysis was per-
formed to study the odds of ADRB2 gene variants on insulin
resistance. Data were dichotomised into (i) non-insulin-
resistant and insulin-resistant groups (using a cutoff of
HOMA-IR≥ 1.7 [22]).
Differences in means between gene variants in anthro-
pometric, blood biochemical, and dietary parameters in
obese and nonobese groups were assessed by using one-way
analysis of covariance (ANCOVA). Adjustment for cova-
riates such as age, gender, physical activity status, smoking
status, alcohol consumption, BMI, WC, fat mass, body fat
percent, and total energy intake were applied where ap-
propriate. *e intake of macronutrients (energy-adjusted)
was dichotomised into two groups based on the median
intake of the population. Amultivariate general linear model
(GLM) was used to investigate the effect of the interaction
between dietary macronutrients and ADRB2 rs1042713 on
obesity-related metabolic traits, after adjusting for potential
confounders (age, gender, physical activity status, smoking
status, alcohol consumption, BMI, and total energy intake).
A statistical probability level of p< 0.05 (two-sided) was
considered significant. No significant association was found
between rs1042713 and protein and carbohydrate intake on
obesity-related traits. *erefore, the results were not
reported.
3. Result
3.1. Baseline Characteristics. In total, 178 Malaysian adults
(female� 154; male� 24) were recruited for anthropometric
measurement and genetic analysis. For biochemical and
dietary analysis, 126 participants (female� 106, male� 20)
were available. General characteristics of the study partici-
pants are reported in Table 1. *e ages between the two
groups (AA vs AG+GG) did not differ significantly
(43.4± 1.8 y vs 41.1± 1.0 y; p � 0.286). *e gender distri-
bution was not significantly different between the gene
variants in the genotype groups (AA vs AG+GG), females
(84.1% vs 87.3%), and males (15.9% vs 12.7%) (p � 0.587).
Ethnicity distribution was not significantly different between
the two genotype groups (p � 0.556). No significant
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difference was found in physical activity (p � 0.256),
smoking (p � 0.606), and alcohol consumption (p � 0.717)
between the two genotype groups. No significant difference
was found in height (p � 0.907), body weight (p � 0.505),
and BMI (p � 0.427) between the two genotype groups
(p> 0.05). Due to the higher number of female participants,
all data analyses were adjusted for by gender.
3.2. Allele Frequencies of the Gene Variants of ADRB2
rs1042713. G allele was the most frequent variant in our
study population (51.1%). *e allele frequency for the minor
allele of rs1042713 (A allele) was 0.49, which did not deviate
from Hardy–Weinberg equilibrium as tested by the chi-
squared test, χ2 � 0.36 (χ2< 3.841) (Table 2).
3.3. Association between ADRB2 rs1042713 and Obesity and
Insulin Resistance. Logistic regression was performed to
examine the independent effect of ADRB2 rs1042713 on the
odds of obesity and insulin resistance. We found no sig-
nificant association between ADRB2 rs1042713 and obesity
(obesity as defined by BMI≥ 27.5 kg/m2) under codominant
(AG p � 0.548 and GG, p � 0.884), dominant (p � 0.725),
and recessive (p � 0.538) models, after adjusting for cova-
riates age, gender, physical activity status, smoking status,
and alcohol consumption (Table 2).
However, our results revealed significant association be-
tween ADRB2 rs1042713 and insulin resistance (using a cutoff
of HOMA-IR≥ 1.7) (Table 3). *e carriers of GG genotype of
rs1042713 had increased odds of insulin resistance, compared to
AA genotype in both codominant and dominant models, 4.43
(CI� 1.31–15.0, adjusted p � 0.016) and 2.83 (CI� 1.04–7.70,
adjusted p � 0.042), respectively, even after adjusting for
covariates age, gender, BMI, physical activity status, smoking
status, and alcohol consumption. No significant association was
found in the recessive model (adjusted p � 0.060).
3.4. Differences in Means between ADRB2 rs1042713 Gene
Variants in Anthropometric, Biochemical, and Dietary Pa-
rameters in Obese and Nonobese Groups. *e age, anthro-
pometric, biochemical, and dietary parameters of the study
participants between gene variants in obese and nonobese
groups have been reported in Table 4. In obese participants,
we found that the carriers of G allele of rs1042713 had sig-
nificantly higher total cholesterol (p � 0.011), LDL choles-
terol levels (p � 0.008), and total cholesterol per HDL
cholesterol ratio (p � 0.048), compared to the noncarriers
(AA), even after adjusting for covariates age, gender, BMI,
WC, fat mass, body fat percent, physical activity status,
smoking status, and alcohol consumption. Interestingly, such
differences in blood biochemical parameters within genotypes
were not observed in the nonobese group. With respect to
dietary parameters, we found that the carriers of the G allele
had significantly lower consumption of PUFA compared to
the noncarriers (AA), even after adjusting for covariates
(p � 0.036). No significance association was found between
ADRB2 rs1042713 and others dietary parameters.
3.5. Differences between Blood Biochemical Parameters and
Respective Diagnostic Cutoffs in Obese Individuals Carrying
ADRB2 rs1042713 GAllele. In obese individuals carrying the
G allele of ADRB2 rs1042713, HOMA-IR was significantly
higher than the diagnostic cut off (2.8± 0.3) (Table 5). Al-
though HDL cholesterol levels (1.5± 0.1mmol/L) were pos-
itively, significantly higher than 1mmol/L (diagnostic cutoff),
total cholesterol (5.7± 0.1mmol/L) and LDL cholesterol levels
(3.6± 0.1mmol/L) were significantly higher than the re-
spective cutoffs, indicating metabolic risk (Table 5).
3.6. Interaction between Dietary Fat Intake and ADRB2
rs1042713 on Fasting Glucose Levels, Insulin Levels, and
HOMA-IR. *e multivariate general linear model was
performed to investigate the effect of ADRB2 rs1042713 and
dietary macronutrients on phenotypic variations. In our
study, our results revealed that, irrespective of obesity, the
carriers of GG genotype of rs1042713 had significantly lower
fasting glucose levels with low SFA intake (<7.3% of TE/day)
(FBG: 4.92± 0.1mmol/L vs 5.80± 0.3mmol/L, p � 0.011)
(Figure 1(a)) and high PUFA : SFA ratio (≥0.8/day) (FBG:
4.83± 0.1mmol/L vs 5.93± 0.4mmol/L, p � 0.006)
(Figure 1(b)), even after adjusting for covariates age, gender,
BMI, physical activity status, smoking status, alcohol con-
sumption, and total energy intake.
Table 1: General characteristics of the study participants; differ-
ences between ADRB2 rs1042713 gene variants.
Genotype
ADRB2 rs1042713 (dominant model)
AA
(n � 44)
AG+GG
(n � 134)
p
value
Age (years) 43.4± 1.8 41.1± 1.0 0.286
Gender
Female (n) 37 (84.1%) 117 (87.3%) 0.587
Male (n) 7 (15.9%) 17 (12.7%)
Ethnicity
Malays 20 (23.3%) 66 (46.7%) 0.556
Chinese 13 (31%) 29 (69%)
Indians 11 (22%) 39 (78%)
Physical activity status
Physically active 41 (24%) 130 (76%) 0.256
Physically inactive 3 (42.9%) 4 (57.1%)
Smoking status
Never 44 (25%) 132 (75%) 0.606
Former 0 1 (100%)
Current 0 2 (100%)
Alcohol consumption
status
Never 44 (25.1%) 131 (74.9%) 0.717
Former 0 1 (100%)
Current 0 1 (100%)
Weight (kg) 65.7± 1.1 68.1± 1.6 0.505
Height (cm) 157.9± 1.1 157.8± 0.6 0.907
BMI (kg/m2) 26.3± 0.7 27.2± 0.5 0.427
ap value based on the independent t-test. bp value based on the chi-squared
test. p< 0.05 was considered as significant. Physically active was defined as
accumulation of at least 150minutes/week of moderate intensity activity
(3–6 METs) or 60minutes/week of vigorous physical activity (>6 METs) as
defined by the Ministry of Health Malaysia [23].
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Moreover, the carriers of GG genotype of rs1042713
with high PUFA intake (≥6% of TE/day) had significantly
lower HOMA-IR (1.5 ± 0.3 vs 3.0 ± 0.7, p � 0.026)
(Figure 2(a)) and fasting insulin levels (6.8 ± 1.6 µU/mL vs
11.4 ± 2.1 µU/mL, p � 0.036) (Figure 2(b)) compared to
low intake.
4. Discussion
Single-nucleotide polymorphism (SNP) in ADRB2
rs1042713 causes alterations in the structural conformation
of the receptor which eventually affect the function of
β-adrenergic receptors (ADRB) [27]. *is may influence the
binding of catecholamines to the beta-2 adrenoceptors and
hence alter lipolysis. A meta-analysis involving 18 published
articles revealed that there was no association between
rs1042713 and obesity [28]. Contrary to the latter, studies on
the Saudi population reported significant association be-
tween ADRB2 rs1042713 polymorphism and the develop-
ment of obesity, as also with insulin resistance and
dyslipidemia [10, 11]. However, findings from Asian pop-
ulations (Japanese and Korean) reported negative
Table 3: Genotype distribution and allele frequency of ADRB2 rs1042713 in insulin-resistant and non-insulin-resistant groups.
Genotype HOMA< 1.7 n � 69 HOMA≥ 1.7 n � 57 Unadjusted OR (95% CI) p value Adjusted OR (95% CI)∗ p value∗
Codominant model
AA 21 (30.5%) 9 (15.8%) 1 — 1 —
AG 33 (47.8%) 30 (52.6%) 2.12 (0.84–5.35) 0.111 2.31 (0.81–6.61) 0.118
GG 15 (21.7%) 18 (31.6%) 2.80 (1.0–7.91) 0.052 4.43 (1.31–15.0) 0.016
Dominant model
AA 21 (30.5%) 9 (15.8%) 1 — 1 —
AG+GG 48 (69.5%) 48 (84.2%) 2.33 (0.97–5.61) 0.058 2.83 (1.04–7.70) 0.042
Recessive model
AA+AG 54 (78.3%) 39 (68.4%) 1 — 1 —
GG 15 (21.7%) 18 (31.6%) 1.66 (0.75–3.70) 0.213 2.46 (0.96–6.27) 0.060
Allele frequency
A 75 (54.3%) 48 (42.1%)
G 63 (45.7%) 66 (57.9%)
Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated for each genotype by logistic regression to determine the risk of insulin resistance
associated withADRB2 rs1042713. p≤ 0.05 was considered as significant. ∗Adjusted for age, BMI, gender, physical activity status, smoking status, and alcohol
consumption. Non-insulin-resistant and insulin-resistant groups were dichotomised using a cutoff of HOMA-IR≥ 1.7 [22].
Table 2: Genotype distribution and allele frequency of ADRB2 rs1042713 in obese and nonobese groups.
Genotype Overall
n � 178
Χ2
(Hardy–Weinberg)
Obese
BMI≥ 27.5
n � 79
Nonobese
BMI< 27.5
n � 99
Unadjusted OR
(95% CI)
p
value
Adjusted OR
(95% CI)∗ pvalue∗
Codominant model
AA 44(24.7%) 0.36 19 (24.0%) 25 (25.2%) 1 — 1 —
AG 86(48.3%) 41 (51.9%) 45 (45.5%)
1.20
(0.58–2.49) 0.627
1.26
(0.59–2.71) 0.548
GG 48(27.0%) 19 (24.1%) 29 (29.3%)
0.86
(0.38–1.98) 0.726
0.94
(0.40–2.23) 0.884
Dominant model
AA 44(24.7%) 19 (24.0%) 25 (25.2%) 1 — 1 —
AG+GG 134(75.3%) 60 (76.0%) 74 (74.8%)
1.07
(0.54–2.12) 0.853
1.14
(0.56–2.33) 0.725
Recessive model
AA+AG 130(73.0%) 60 (75.9%) 70 (70.7%) 1 — 1 —
GG 48(27.0%) 19 (24.1%) 29 (29.3%)
0.76
(0.39–1.50) 0.434
0.80
(0.40–1.61) 0.538
Allele frequency
A 174(48.9%) 79 (50.0%) 95 (48.0%)
G 182(51.1%) 79 (50.0%) 103 (52.0%)
*e agreement of genotype frequencies with Hardy–Weinberg equilibriumwas tested by using the chi-squared test, with χ2< 3.841 considered as no deviation
from Hardy–Weinberg equilibrium. Logistic regression was conducted to determine the risk of obesity associated with gene variants. Odds ratios (ORs) with
95% confidence intervals (95% CIs) were estimated for each genotype. ∗Adjusted for age, gender, physical activity status, smoking status, and alcohol
consumption. p< 0.05 was considered significant.
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Table 4: Differences in means (±SE) between ADRB2 rs1042713 gene variants in anthropometric, biochemical, and dietary parameters in
obese and nonobese groups.
ADRB2 rs1042713 (dominant model)
Obese (n � 79) Nonobese (n � 99)
General characteristics AA (n � 19) AG+GG (n � 60) p value AA (n � 25) AG+GG (n � 74) p value
Age (years) 47.8 ± 2.0 42.8 ± 1.5 0.038∗ 40.0± 2.7 39.7± 1.3 0.958
1Weight (kg) 76.0± 2.0 81.2± 2.3 0.097 57.9± 1.9 57.4± 1.0 0.957
1Height (cm) 157.7± 1.7 157.7± 1.0 0.688 158.1± 1.5 157.9± 0.8 0.871
1BMI (kg/m2) 30.5± 0.5 32.4± 0.6 0.086 23.0± 0.6 23.0± 0.3 0.936
1WC (cm) 97.6± 2.2 99.4± 1.6 0.173 68.6± 3.7 68.6± 2.0 0.899
1WHR 0.90± 0.01 0.93± 0.01 0.117 0.87± 0.01 0.87± 0.01 0.728
1Muscle mass (kg) 24.0± 0.9 24.4± 0.7 0.525 20.9± 1.0 20.9± 0.6 0.941
1Fat mass (kg) 32.3± 1.2 36.6± 1.4 0.065 19.2± 1.0 19.5± 0.6 0.887
1Fat-free mass (kg) 43.8± 1.6 44.6± 1.2 0.475 38.6± 1.6 37.9± 0.7 0.678
1Percent body fat (%) 42.5± 1.2 44.8± 0.7 0.110 33.3± 1.3 33.8± 0.8 0.683
1Systolic BP (mmHg) 124.0± 3.6 124.0± 2.0 0.712 122.6± 5.0 119.6± 2.3 0.587
1Diastolic BP (mmHg) 81.0± 2.3 81.5± 1.3 0.535 81.9± 2.7 79.2± 1.8 0.588
1Pulse rate (bpm) 75.7± 2.5 76.1± 1.3 0.948 75.1± 4.5 77.9± 2.0 0.556
Blood biochemical parameters AA (n � 19) AG+GG (n � 60) p value AA (n � 11) AG+GG (n � 36) p value
2Fasting glucose (mmol/L) 5.1± 0.2 5.3± 0.3 0.509 5.0± 0.3 5.2± 0.3 0.561
2Fasting insulin (uU/mL) 7.74± 1.6 11.2± 1.3 0.209 11.7± 3.7 7.5± 1.4 0.361
2HOMA-IR 1.9± 0.5 2.8± 0.3 0.176 2.9± 1.0 2.2± 0.7 0.494
2Total cholesterol (mmol/L) 5.0 ± 0.2 5.7 ± 0.1 0.011∗ 5.4± 0.3 5.6± 0.2 0.942
2Triglyceride (mmol/L) 1.2± 0.2 1.4± 0.1 0.083 1.7± 0.4 1.4± 0.1 0.983
2HDL cholesterol (mmol/L) 1.6± 0.1 1.5± 0.1 0.791 1.5± 0.1 1.6± 0.1 0.636
2LDL cholesterol (mmol/L) 2.9 ± 0.2 3.6 ± 0.1 0.008∗ 3.3± 0.4 3.3± 0.2 0.650
2Total cholesterol/HDL cholesterol 3.4 ± 0.2 3.9 ± 0.1 0.048∗ 3.7± 0.3 3.7± 0.2 0.650
2hsCRP (mg/L) 5.2± 1.5 8.8± 1.4 0.059 2.2± 0.5 2.9± 0.5 0.750
Dietary parameters AA (n � 19) AG+GG (n � 60) p value AA (n � 11) AG+GG (n � 36) p value
3Total energy intake (kcal) 2145.5± 108.0 2065.6± 41.7 0.766 1897.5± 53.6 1867.5± 47.4 0.836
4Actual total carbohydrate intake (g) 272.3± 20.7 259.4± 7.2 0.967 237.8± 13.1 234.0± 11.0 0.625
4Actual total protein intake (g) 75.1± 5.3 77.1± 3.1 0.982 72.8± 5.3 70.0± 3.2 0.276
4Actual total dietary fat intake (g) 90.2± 5.5 84.7± 3.1 0.810 77.1± 4.1 77.7± 2.6 0.817
4Percentage energy from carbohydrate (%) 46.9± 1.8 46.9± 1.2 0.995 46.8± 2.1 47.7± 1.3 0.520
4Percentage energy from protein (%) 13.8± 0.6 14.9± 0.5 0.799 15.5± 1.2 14.4± 0.7 0.181
4Percentage energy from dietary fat (%) 37.9± 1.9 36.4± 1.0 0.744 36.4± 1.5 36.8± 1.1 0.968
4SFA (%TE) 7.0± 1.0 7.6± 0.5 0.514 7.0± 0.8 8.7± 0.6 0.307
4MUFA (%TE) 11.8± 1.1 10.3± 0.6 0.339 11.8± 1.1 12.1± 0.6 0.895
4PUFA (%TE) 8.0 ± 0.8 5.6 ± 0.4 0.036∗ 6.5± 1.1 7.0± 0.6 0.523
4Trans fat (%TE) 0.1± 0.01 0.1± 0.04 0.109 0.1± 0.03 0.1± 0.02 0.497
4Dietary cholesterol (%TE) 88.8± 14.0 108.3± 10.5 0.987 111.4± 22.9 109.7± 16.1 0.471
One-way analysis of covariance was performed to determine the differences between means between gene variants in anthropometric, biochemical, and
dietary parameters in obese and nonobese participants, after adjusting for covariates in different model 1age, gender, physical activity status, smoking status,
and alcohol consumption; 2model1 + BMI, WC, body fat mass, and body fat percent; 3model1 + BMI; and 4model3 + total energy intake. ∗p< 0.05 was
considered significant. HOMA-IR: homeostatic model assessment-insulin resistance; HDL: high-density lipoprotein; LDL: low-density lipoprotein; hsCRP:
high-sensitivity C-reactive protein; SFA: saturated fatty acid; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; % TE: percentage of total
energy intake.
Table 5: Differences between blood biochemical parameters and respective diagnostic cutoffs in obese individuals carrying ADRB2
rs1042713G allele.
Blood biochemical parameters Mean (±SE) Diagnostic cutoff p value
Fasting glucose (mmol/L) 5.3± 0.3 5.6 [24] 0.327
Fasting insulin (µU/mL) 11.2± 1.3 10.6 [25] 0.330
HOMA-IR 2.8 ± 0.3 1.7 [22] 0.003∗
Total cholesterol (mmol/L) 5.7 ± 0.1 5.2 [26] 0.001∗
Triglyceride (mmol/L) 1.4 ± 0.1 1.7 [24] <0.001∗
HDL cholesterol (mmol/L) 1.5 ± 0.1 1.0 [24] <0.001∗
LDL cholesterol (mmol/L) 3.6 ± 0.1 2.6 [26] <0.001∗
Total cholesterol/HDL cholesterol 3.9± 0.1 — —
*e one-sample t-test was performed to assess the difference between blood biochemical parameters and respective diagnostic cutoffs ∗p< 0.05 was
considered significant. HOMA-IR: homeostatic model assessment-insulin resistance; HDL: high-density lipoprotein; LDL, low-density lipoprotein.
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association between obesity and ADRB2 gene poly-
morphisms [12, 13]. Moreover, these studies did not in-
vestigate interaction of gene variants, phenotypes, and
dietary nutrients. To date, there are no data reported on
ADRB2 rs1042713 in the Malaysian population. To the best
of our knowledge, this is the rst study that investigates the
eect of ADRB2 rs1042713 on obesity and obesity-related
metabolic parameters and its interaction with dietary nu-
trients in Malaysian adults.
4.1. Association between ADRB2 rs1042713 and Obesity and
Insulin Resistance. In our study, we found no association
between ADRB2 rs1042713 and odds of obesity (obesity was
dened as BMI≥ 27.5 kg/m2). However, ADRB2 rs1042713
was associated with insulin resistance (using a cuto of
HOMA-IR≥ 1.7). We found that the carriers of G allele of
rs1042713 had increased odds of insulin resistance com-
pared to the noncarriers (AA), in the dominant model, even
after adjusting for potential confounders. ese ndings
0
1
2
3
4
5
6
7
AA AG GG
Fa
sti
ng
 g
lu
co
se
 le
ve
ls 
(m
m
ol
/L
)
ADRB2 rs1042713
Low SFA intake
High SFA intake
p = 0.968 p = 0.301 p = 0.011∗
(a)
0
1
2
3
4
5
6
7
AA AG GG
Fa
sti
ng
 g
lu
co
se
 le
ve
ls 
(m
m
ol
/L
)
ADRB2 rs1042713
Low PUFA:SFA ratio
High PUFA:SFA ratio
p = 0.301 p = 0.548 p = 0.006
∗
(b)
Figure 1: e eect of the interaction between ADRB2 rs1042713 and (a) SFA intake and (b) PUFA : SFA ratio. SFA and PUFA : SFA ratios
were dichotomised into two groups by using the median value of 7.3% of TE/day and 0.8/day (for all participants), respectively, for analysis.
Gene-diet interaction was evaluated by using the multivariate general linear model after adjusting for age, gender, BMI, physical activity
status, smoking status, alcohol consumption, and total energy intake. ∗p< 0.05 was considered statistically signicant. SFA: saturated fatty
acid; PUFA: polyunsaturated fatty acid.
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Figure 2: e eect of the interaction between ADRB2 rs1042713 and PUFA intake on (a) HOMA-IR and (b) fasting insulin levels. PUFA
intake was dichotomised into two groups by using the median value of 6% of TE/day (for all participants) for analysis. Gene-diet interaction
was evaluated by using the multivariate general linear model after adjusting for age, gender, BMI, physical activity status, smoking status,
alcohol consumption, and total energy intake. ∗p< 0.05 was considered statistically signicant. PUFA: polyunsaturated fatty acid; HOMA-
IR: homeostatic model assessment-insulin resistance.
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suggest that variations in ADRB2 rs1042713 may interfere
with glucose homeostasis and cause insulin resistance. Prior
et al. reported that ADRB2 Arg16Gly–Gln27Glu haplotype
was associated with glucose intolerance and insulin re-
sistance in obese postmenopausal women [29]. A possible
explanation for this observation could be the alteration in
the structural conformation of the receptor, which may have
enhanced sympathetic stimulation leading to increased li-
polysis [8]. *is overstimulation of ADRB2 is found to be
associated with the pathogenesis of insulin resistance as it
inhibits the insulin-induced translocation of GLUT4 and
reduces glucose uptake via the cAMP-dependent protein
kinase A-dependent pathways [30].
We found that HOMA-IR in the obese individuals
carrying G allele of ADRB2 rs1042713 was above the di-
agnostic cutoff (1.7). It is now an established fact that higher
levels of nonesterified fatty acids (NEFA) in the blood can
induce preferential use of free fatty acids over glucose to
generate ATP even in the presence of insulin in muscle and
adipose tissue resulting in hyperglycaemia [31, 32]. Stimu-
lation by noradrenaline of adipose tissue ADRB2 increases
the release of NEFA. In addition, free fatty acids (FFAs) can
stimulate hepatic gluconeogenesis and alter pancreatic in-
sulin release and subsequent metabolism in individuals with
impaired glucose metabolism [33].
4.2. Association between ADRB2 rs1042713 and Blood Lipid
Levels. In the present study, we report that obese individuals
carrying the G allele of rs1042713 had significantly higher
total cholesterol, LDL cholesterol levels, and total cholesterol
per HDL cholesterol ratio compared to the noncarriers (AA).
Total cholesterol (5.7± 0.1mmol/L) and LDL cholesterol
levels (3.6± 0.1mmol/L) in obese individuals carrying the G
allele were above the diagnostic cutoffs (5.2mmol/L and
2.6mmol/L, respectively [26]). However, these differences in
biochemical parameters were not observed in nonobese in-
dividuals. In our participants, excess FFAs in circulation in
obese individuals carrying the gene variants of ADRB2 may
have driven dyslipidemia. Increased lipolysis due to the
polymorphisms of ADRB2 gene may have caused increased
levels of NEFA induced hepatic production of VLDL and
hence higher LDL levels in our participants [34].
4.3. Interaction between Dietary Fats and ADRB2 rs1042713
on Glycaemic Indices. We report that the level of fasting
glucose was modulated by the types of dietary fatty acids
such as SFA and PUFA in the carriers of GG genotype of
ADRB2 rs1042713.*e carriers of GG genotype of rs1042713
had significantly lower fasting glucose levels with intake of
relatively higher PUFA:SFA ratio (≥0.8/day) (Figure 1(b))
and lower SFA intake (<7.3% of TE/day) (Figure 1(a)).
Moreover, the carriers of GG genotype of rs1042713 had
significantly lower fasting insulin levels and HOMA-IR
when consuming higher PUFA intake (≥6% of TE/day).
*ese findings suggest that carriers of GG genotype of
ADRB2 rs1042713 consuming higher percentage of PUFA
demonstrated better homeostatic control of fasting blood
glucose and insulin sensitivity. A meta-analysis of 102
randomised controlled feeding trials with 4,200 subjects
has reported that PUFA had the most beneficial effects in
improving glycaemia, insulin resistance, and insulin se-
cretion in comparison to dietary carbohydrate, SFA, and
MUFA [35]. *e anti-inflammatory properties of PUFA
increase the production of adiponectin via PPARα acti-
vation and alleviate adipose tissue inflammation via
GPR120 and resolvins/protectins, which favour insulin
sensitivity. It also suppresses oxidative stress and pancre-
atic lipotoxicity, reduces toxicity of tissue free fatty acids,
and increases membrane fluidity [36]. *is body of evi-
dence indicates that the composition of dietary fatty acid
intake plays an important role in affecting glucose meta-
bolism and insulin sensitivity.
As per Malaysian recommendations, 10% of total en-
ergy should come from SFA and 3 to 8% of total energy
should come from PUFA [23]. On an average, dietary
intake of our participants with respect to SFA and PUFA
were within these ranges. However, individuals with G
allele of rs1042713 may need to consume higher quantity of
PUFA to combat diet-related noncommunicable diseases.
Replacing isocaloric quantity of foods rich in SFA with
PUFA may improve homeostatic control of blood glucose
and enhance insulin sensitivity (HOMA-IR) in such
individuals.
5. Limitations
A major limitation of our study is the small sample size. We
acknowledge that the current study is exploratory and is
underpowered to detect the gene-diet interaction between
ADRB2 rs1042713 and dietary nutrients on phenotypic and
metabolic alterations in our population. However, with
association and interaction analysis in the current study, we
have generated a hypothesis. In future, large-scale studies are
required to confirm such findings in the Malaysian pop-
ulation. In this study, we did not stratify our participants by
gender for analysis due to the small sample size of male
participants. To account for this, we have adjusted for gender
statistically in all our data analysis to eliminate Type 1 error.
6. Conclusion
In conclusion, our study revealed that there was no asso-
ciation between ADRB2 rs1042713 and obesity. However,
ADRB2 rs1042713 was associated with insulin resistance in
Malaysian adults. *e carriers of G allele of rs1042713 had
increased odds of insulin resistance compared to noncarriers
(AA). Obese individuals carrying the G allele of rs1042713
had significantly higher total cholesterol, LDL cholesterol
levels, and total cholesterol per HDL cholesterol ratio
compared to the noncarriers (AA). *ese differences were
not observed in nonobese individuals. *ere is evidence
from earlier studies that high PUFA intake is associated with
favourable effects on glycaemia and insulin resistance. Over
and above the latter, we found that higher PUFA intake was
beneficial in individuals carrying the G allele with respect to
glycaemic indices compared to the noncarriers. Although it
is premature to report gene-diet interaction on the
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regulation of glucose and insulin levels in Malaysians, we
suggest that higher quantity of PUFA-rich food sources in
regular diet may benefit overweight and obese Malaysian
adults metabolically. Large-scale studies are required to
replicate and confirm the current findings in the Malaysian
population.
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